Pfizer (PFE) Inventory Average (2009 - 2026)

Pfizer (PFE) has reported Inventory Average for 18 consecutive years, with $10.3 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Inventory Average fell 8.48% year-over-year to $10.3 billion in Q2 2026; TTM through Jun 2026 was $10.3 billion, a 8.48% decrease from a year earlier, with the FY2025 full-year figure at $10.8 billion, down 4.73% from the prior year.
• Inventory Average was $10.3 billion for Q2 2026 at Pfizer, down from $10.7 billion in the prior quarter.
• Over five years, Inventory Average peaked at $11.6 billion in Q3 2024 and troughed at $9.3 billion in Q2 2023.
• A 5-year average of $10.7 billion and a median of $10.8 billion in 2025 frame the typical range for Inventory Average.
• Across the five-year window, Inventory Average grew 17.15% in 2022 and decreased 8.48% in 2026, its largest moves.
• Over 5 years, Inventory Average stood at $10.2 billion in 2022, then fell by 2.85% to $9.9 billion in 2023, then grew by 13.71% to $11.3 billion in 2024, then dropped by 1.99% to $11.1 billion in 2025, then slipped by 6.83% to $10.3 billion in 2026.
• The last three Inventory Average figures came in at $10.3 billion (Q2 2026), $10.7 billion (Q1 2026), and $11.1 billion (Q4 2025), per Business Quant data.